GCA candidate Tremfya fails to meet clinical trial objectives

[Optim11]

Here in the US, Johnson & Johnson announced today it is halting its Phase 2 "THEIA" trial as the numbers of enrolled GCA patients did not, unfortunately, achieve the level of remission hoped for. If you're inclined to read the technical details, you can google Janssen Rheumatology's data.

[PMRpro Ambassador]

Hmmm - doesn't seem entirely surprising to me since it is an IL-23 inhibitor and as yet I don't think there is clear evidence that it is a majority shareholder in GCA. It may be part of the story for the 50% who don't respond entirely to Actemra but surely the results with Actemra suggest that the bulk of inflammation is IL-6 related for at least half of patients and in the other half it plays a large role. However - immunology is a dreadfully complex field and I don't pretend to understand it!

This is a good read though

frontiersin.org/journals/im...

[AtopicGuy]

Here's a summary:

fiercepharma.com/pharma/aft...